WO1998035674A1 - Compositions permettant d'inhiber la resorption osseuse - Google Patents

Compositions permettant d'inhiber la resorption osseuse Download PDF

Info

Publication number
WO1998035674A1
WO1998035674A1 PCT/GB1998/000443 GB9800443W WO9835674A1 WO 1998035674 A1 WO1998035674 A1 WO 1998035674A1 GB 9800443 W GB9800443 W GB 9800443W WO 9835674 A1 WO9835674 A1 WO 9835674A1
Authority
WO
WIPO (PCT)
Prior art keywords
antagonist
medicament according
medicament
nmda
receptor
Prior art date
Application number
PCT/GB1998/000443
Other languages
English (en)
Inventor
Timothy Michael Skerry
Larry John Suva
Original Assignee
Smith & Nephew Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smith & Nephew Plc filed Critical Smith & Nephew Plc
Priority to AU60017/98A priority Critical patent/AU6001798A/en
Priority to CA002280722A priority patent/CA2280722A1/fr
Priority to JP53547798A priority patent/JP2001513757A/ja
Priority to EP98903203A priority patent/EP0971712A1/fr
Publication of WO1998035674A1 publication Critical patent/WO1998035674A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Definitions

  • the present invention relates to the field of bone biochemistry and is concerned in particular with the provision of medicaments for the treatment of diseases of the bone.
  • the present invention is also concerned with novel usage for known materials and compositions and processes for the preparation of the same.
  • Vertebrate bone as a tissue providing mechanical support for the body, undergoes constant remodelling through the formation and reso tion of bone mediated, it is widely thought, by the activities of osteoblasts and osteoclasts respectively.
  • Bone remodelling comprises a complex and highly organised interaction between cells and the extracellular matrix (ECM).
  • ECM extracellular matrix
  • the remodelling process is, however, adaptive in response to requirements for growth or environmental stressing.
  • the rate of bone formation approximates with the rate of bone resorption, a process known as coupling.
  • Bone resorption or formation is not, though, a generalised feature of the skeleton but occurs in discrete sites which may be surrounded by areas of quiescent bone. Where resorption occurs excessively, several clinical problems can occur either at a specific locality or more extensively throughout the skeleton.
  • osteoporosis is a disease that is characterised by abnormalities in the amount and architectural arrangement of bone tissue. Osteoporosis results from excessive resorption of bone and is a major clinical condition that can lead to fractures of bone following only minimal trauma. In addition to the distress to sufferers, the direct hospital costs of osteoporosis have been estimated, in the U.S. only, to approach $5.2 billion for women alone (Phillips et al (1988), Bone 9:271-279). The term Osteoporosis' in fact refers to a group of conditions that are associated with loss of bone tissue and an accompanying architectural abnormality that occurs in cancellous bone space.
  • post menopausal osteoporosis When the condition develops in post-menopausal women it is referred to as post menopausal osteoporosis. Fractures occur commonly in the hip, spine and distal radius and is considered by many countries to be a major public health problem (Lindasay R (1993), Clinical Rheumatology Osteoporosis; V.7, No.3). While diet and life-style appear to be factors in the pathogenesis of the disease, loss of ovarian function is an important determinant, at least in post menopausal osteoporosis.
  • osteoporotic-associated disease states include steroid induced osteoporosis, idiopathic juvenile osteoporosis, post- transplantation osteoporosis where bone resorption is a secondary indication of disorder.
  • Paget's disease In a disease of old age known as Paget's disease, there is excessive osteoclastic resorption of bone and reorganisation with loss of structure leading to deformities and liability to fracture.
  • osteoclastomas and other primary and secondary tumours often cause resorption and subsequent increased liability to fracture.
  • Tumour induced osteolysis may also lead to pathologically raised serum calcium levels which are believed to increase significantly morbidity in cancer patients.
  • JP 63-295561 2-quinolone derivatives are disclosed which are described as having potent bone absorption-inhibiting activity.
  • N-methyl-D-Aspartate (NMDA) like receptor antagonists have a history of use in the field of medicine in treating disorders, primarily conditions such as neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycaemia and surgery as well as treating neurodegenerative diseases such as Alzheimer's disease, amyotrophic lateral sclerosis, Huntingdon's disease, Down's syndrome, chronic pain, opiate tolerance and the like.
  • NMDA like receptors principally thought of as present in the central nervous system (CNS) where they are believed to be involved in processes such as learning and development are also present on the surface of at least osteoclasts, the cells mainly responsible for bone resorption and furthermore that the inhibitors of this receptor inhibit osteoclast activity.
  • NMDA-receptor antagonist in the manufacture of a medicament for the treatment of diseases or clinical conditions featuring or characterised by undesired bone resorption.
  • a method for the treatment of diseases or clinical conditions as hereinbefore described comprising the step of; administering a therapeutically effective amount of a NMDA-receptor antagonist.
  • a prophylactic method for the prevention of diseases or clinical conditions as hereinbefore described comprising the steps of repeated administration of a therapeutically effective amount of a NMDA-receptor antagonist.
  • NMDA-receptor antagonist in the manufacture of a medicament for the treatment of diseases of bone mass deficiency.
  • NMDA-receptor antagonist as used herein is meant a medicinal composition that inhibits the biological action triggered by the binding of glutamate or other natural ligand to a NMDA receptor or subtype thereof present on the surface of osteoclasts or other bone cell type.
  • This may include, for example, reversible and irreversible competitive binding-site receptor inhibitors or other inhibitors (for example non-competitive inhibitor) that bind to a portion of the NMDA receptor and inhibits its activation for example glycine NMDA associated antagonists, glutamate site NMDA receptor antagonists and polyamine site antagonists.
  • Other inhibitors include e.g. an NMDA receptor antibody or Fab fragment thereof or other protein moiety. Those skilled in the art will also recognise that this may include anti-sense mRNA capable of inhibiting translation of NMDA-receptor mRNA within osteoclasts.
  • the present invention is aimed at the treatment of undesired bone resorption which may often involve excessive resorption.
  • the disease or clinical condition may feature bone resorption i.e. bone resorption is a secondary indication of the disorder.
  • bone resorption may characterise, i.e. be the primary indication of the disorder.
  • Multi-nucleated osteoclasts are characterised by a high degree of expression of the enzyme Tartrate Resistant Acid Phosphatase (TRAP), an assay for which is disclosed in Barka et al: (1962) J Histochem Cytochem; 10,p741-753 and incorporated herein by reference.
  • TRIP Tartrate Resistant Acid Phosphatase
  • the receptor-antagonist of the present invention is preferably one which by virtue of its form (e.g. association with a carrier) and/or route of administration, does not cross to a significant extent the blood-brain barrier.
  • osteoporosis including osteoporosis of disuse, Sch ⁇ ller's disease, post menopausal osteoporosis, post- traumatic osteoporosis, senile osteoporosis
  • Paget's disease undesired bone resorption featured in cancer, renal disease, fracture healing, rheumatoid arthritis and other arthritic conditions.
  • a receptor-antagonist previously used with respect to the CNS may be modified for use in the manufacture of medicament according to the present invention by for example modifying lipid solubility or increasing the charge on the receptor-antagonist such as known to those skilled in the art.
  • Other possibilities include labile coupling of the receptor-antagonist to a 'bone-seeking' substance such as Tetracyclines, Bisphosphonates or antibody.
  • NMDA-receptor antagonists previously thought of as having minimum therapeutic use because of their inability to penetrate the blood/brain barrier effectively to treat CNS disorders may be useful in the present invention.
  • NMDA associated antagonists such as 5,7 dichlorokynurenic acid and indole-2- carboxylic acid have been regarded as ineffectual as therapeutic agents for treating disorders associated with the NMDA receptor because of their inability to cross this barrier (McNarmara, D et al; Neurosci.Lett; 120;17-20 (1990) and Gray N.M et al, J.Med. Chem; 34 1283 to 1292 (1991).
  • the NMDA receptor-antagonist for use in the present invention may be selected from a group consisting of, but not limited to;
  • Preferred tartrates include (7)-2-(4-benzyl piperidino-1)-p- hydroxyphenyl propanol tartrate (Cas No. 23210-58-4, Validex®, Hoechst Marion Roussel).
  • Preferred maleate include hydrogen maleates such as MK-801 hydrogen maleate (Merck, Sharpe and Dohme Inc)
  • Preferred phosphonopentanoic acids include D(-)-2-amino-5- phosphonopentanoic acid, (Research Biochemicals International RBI) and D,L-2-amino-5-phosphonovaleric acid (RBI)
  • Glycine NMDA associated antagonists include various heterocyclic compounds and especially aromatic heterocyclic compounds.
  • Glycine NMDA associated inhibitors of the invention can be selected from the group quinolones, quinoxalinediones, indole-2-carboxylates and 6-phenyl pyrazinones.
  • the aromatic aryl ring preferably comprises a halo, e.g. chloro, substituted aryl ring.
  • quinolones are 7-chloro-2-quinolones, for example; 7-chloro-4-hydroxy-3-(3-phenoxyphenyl)-2(1 H)- quinolinone; 7-chloro-4-hydroxy-3-methoxycarbonyl-2-quinolone; or 7-chloro-4-hydroxy-2-(4-methoxy-2-methylphenyl) pyridazino[4,5-b] quinoline-1 ,10(2H,5H)-dione monosodium salt.
  • Preferred quinoxalinediones are 7-chloro-quinoxaline-2,3- diiones for example; 7-chloro-6-methyl-5-nitro,14- dihydroquinoxaline; 6,7-dichloro-5-nitro-1 ,4-dihydroquinoxaline-2-3- dione;or (S)-9-chloro-5-[p-aminomethyl-o-(carboxy-methoxy)phenyl- carbamoylmethyl]-6,7-dihydro-1H,5H-pyridol[1 ,2,3-de]quinoxaline- 2,3-dione,e.g. the hydrochloride trihydrate.
  • Preferred indole-2-carboxylates for example, the Glaxo Welcome compound known as GV-150526A.
  • 6-phenyl pyrazinones are 6-(4-chlorophenyl) pyrazinones, for example 6-(4-chlorophenyl)imidazo[1 ,2- ajpyrazinone.
  • receptor antagonists of the present invention are either known per se or may be manufactured according to the teaching of the art, e.g. the manufacture of MK801 is disclosed in US patent 4,399,141.
  • the medicament may be administered orally, subcutaneously, intra-muscularly, intravenously, either systematically but preferably locally, intraperitonealy or transdermally (e.g. skin patches) and may be in a composition form such as tablets, capsules, powders, granules, elixirs for oral administration or in sterile solutions or suspensions for parenteral administration.
  • a composition form such as tablets, capsules, powders, granules, elixirs for oral administration or in sterile solutions or suspensions for parenteral administration.
  • Further composition forms includes pills and suppositories.
  • a therapeutically effective amount of the receptor-antagonist can be determined by routine observation and experimentation and will be dependent on factors such as the clinical condition or disease under treatment, age of the patient, severity and locality of the disease. For example, we have demonstrated that MK801 displays a dose-response relationship with concentrations of 10 ⁇ M showing minimal effect and concentrations of 100 ⁇ M having a maximal effect in vitro.
  • the therapeutically effective amount of the prophylactic prevention of a disease before clinical manifestation does not necessarily correspond to the effective amount for treatment of the clinical condition following manifestation.
  • a therapeutically effective amount of the receptor-antagonist may be combined with a physiologically acceptable vehicle, carrier, excipient, binder, preservative, stabiliser, flavour etc in a unit dosage form as called by accepted pharmaceutical practice.
  • Pharmaceutical compositions of the present invention may comprise the antagonist together with an adjuvant.
  • a binder such as gum tragacanth, acacis, corn starch or gelatin
  • an excipient such as dicalcium phosphate
  • a disintegrating agent such as corn starch, potato starch, alginic acid
  • a lubricant such as magnesium stearate
  • a sweetening agent such as sucrose.
  • a syrup or elixir may contain the receptor-antagonist, sucrose as a sweetening agent, methyl and propyl paralens as preservation, a dye and a flavouring.
  • the present invention is aimed primarily at humans, other animals e.g. mammals such as racehorses or dogs who suffer similar or related disorders of the bone may also benefit from the present invention.
  • osteoclast/osteoblast co-culture was prepared as follows; calvaria from 12-20 new-born mice was dissected (2 to 3 days old Bb/CBA) and osteoblasts were isolated by digestion of the bones in collagenase followed by incubation in EDTA and a second collagenase digestion according to Takahashi U et al, (1988);
  • the long bones were dissected from 2 to 3 adult mice, and the marrow was flushed out with 2 to 4ml Hanks balanced salt solution supplemented with 10% FCS (Gibco/BRL, Paisley, UK) and using a 2SG needle. Pooled marrow sample were then passed through needles of increasing gauge (19G to 25G). Red cells were removed by centrifugation on a cushion of Ficoll-Paque (Pharmacist) at 600 x g for 25 mins. The marrow cells were harvested from the interface, washed once and resuspended in ⁇ -Minimum Essential Medium (MEM) supplemented with 10% FCS and antibiotics (Gibco).
  • MEM ⁇ -Minimum Essential Medium
  • Adherent osteoblasts were resuspended by gentle trypsin treatment and co-cultures of 4 x 10 4 osteoblasts together with 9 x 10 5 bone marrow cells were prepared in wells of a 24 well plate, containing ⁇ -MEM with 10% FCS and 1,25(OH) 2 D 3 (IO nM).
  • test amount of known NMDA-receptor antagonist MK-801 (Merck) and Phencyclidine (PCP) were added for the times described to give the concentrations indicated.

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)

Abstract

La présente invention se base sur l'observation selon laquelle les récepteurs NMDA fonctionnels sont présents sur les ostéoclastes. Cette invention concerne l'utilisation d'antagonistes NMDA pour inhiber la résorption osseuse, ces antagonistes étant utiles au traitement de maladies osseuses, telles que l'ostéoporose et la maladie de Paget. Les antagonistes NMDA utilisés étaient la phencyclidine et la dizocilpine.
PCT/GB1998/000443 1997-02-14 1998-02-12 Compositions permettant d'inhiber la resorption osseuse WO1998035674A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU60017/98A AU6001798A (en) 1997-02-14 1998-02-12 Compositions for the inhibition of bone resorption
CA002280722A CA2280722A1 (fr) 1997-02-14 1998-02-12 Compositions permettant d'inhiber la resorption osseuse
JP53547798A JP2001513757A (ja) 1997-02-14 1998-02-12 骨吸収の阻害用組成物
EP98903203A EP0971712A1 (fr) 1997-02-14 1998-02-12 Compositions permettant d'inhiber la resorption osseuse

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9703109.0 1997-02-14
GBGB9703109.0A GB9703109D0 (en) 1997-02-14 1997-02-14 Compositions

Publications (1)

Publication Number Publication Date
WO1998035674A1 true WO1998035674A1 (fr) 1998-08-20

Family

ID=10807681

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1998/000443 WO1998035674A1 (fr) 1997-02-14 1998-02-12 Compositions permettant d'inhiber la resorption osseuse

Country Status (7)

Country Link
EP (1) EP0971712A1 (fr)
JP (1) JP2001513757A (fr)
AU (1) AU6001798A (fr)
CA (1) CA2280722A1 (fr)
GB (1) GB9703109D0 (fr)
WO (1) WO1998035674A1 (fr)
ZA (1) ZA981206B (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002050302A2 (fr) * 2000-12-21 2002-06-27 Myriad Genetics, Inc. Interactions proteine-proteine
JP2003505514A (ja) * 1999-07-28 2003-02-12 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルベニア 破骨細胞生成を阻害する方法
WO2006094674A1 (fr) * 2005-03-07 2006-09-14 Michael Hermanussen Antagonistes de recepteur nmda dans l'intervention medicale de troubles metaboliques

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992021355A1 (fr) * 1991-05-28 1992-12-10 The Procter & Gamble Company Combinaisons de therapies a base de calcium, d'oligo-elements, de vitamine d et de medicaments
WO1993011115A2 (fr) * 1991-11-29 1993-06-10 Merck Sharp & Dohme Limited Derives de quinolone et leur utilisation comme antagonistes des recepteurs de nmda et ampa
FR2711992A1 (fr) * 1993-11-03 1995-05-12 Lipha Nouveaux dérivé hétérocycliques, procédé de préparation et composition pharmaceutique les contenant.
WO1996021644A1 (fr) * 1995-01-10 1996-07-18 Smithkline Beecham S.P.A. Derives indole utiles dans le traitement de l'osteoporose
WO1997016434A1 (fr) * 1995-11-02 1997-05-09 Pfizer Inc. (-) cis-6(s)-phenyl-5(r)[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronyphthalen-2-ol d-tartrate

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992021355A1 (fr) * 1991-05-28 1992-12-10 The Procter & Gamble Company Combinaisons de therapies a base de calcium, d'oligo-elements, de vitamine d et de medicaments
WO1993011115A2 (fr) * 1991-11-29 1993-06-10 Merck Sharp & Dohme Limited Derives de quinolone et leur utilisation comme antagonistes des recepteurs de nmda et ampa
FR2711992A1 (fr) * 1993-11-03 1995-05-12 Lipha Nouveaux dérivé hétérocycliques, procédé de préparation et composition pharmaceutique les contenant.
WO1996021644A1 (fr) * 1995-01-10 1996-07-18 Smithkline Beecham S.P.A. Derives indole utiles dans le traitement de l'osteoporose
WO1997016434A1 (fr) * 1995-11-02 1997-05-09 Pfizer Inc. (-) cis-6(s)-phenyl-5(r)[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronyphthalen-2-ol d-tartrate

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ANEGAWA ET AL.: "Transfection of N-Methyl-D-Aspartate Receptor in a Nonneuronal Cell Line Leads to Cell Death", J. NEUROCHEM., vol. 64, no. 5, 1995, pages 2004 - 2012, XP002068027 *
CHENU ET AL.: "Glutamate Receptors Are Expressed by Bone Cells and Are Involved in Bone Resorption", BONE, vol. 22, no. 4, 1998, pages 295 - 299, XP002068030 *
GALLOP ET AL.: "IS THE ANTIOXIDANT, ANTI-INFLAMMATORY PUTATIVE NEW VITAMIN, PQQ, INVOLVED WITH NITRIC OXIDE IN BONE METABOLISM", CONNECTIVE TISSUE RESEARCH, vol. 29, no. 2, 1993, pages 153 - 161, XP002068028 *
KLEIN I.E.: "The effect of thyrocalcitonin and growth hormones on bone metabolism", J. PROSTET. DENT., vol. 33, no. 4, 1975, pages 365 - 379, XP002068029 *
PATTON ET AL.: "GLUTAMATE SIGNALLING IN HUMAN AND RAT BONE CELLS", BONE, vol. 20, no. 4 Suppl., 1997, pages 76S, XP002068026 *
REYNOLDS ET AL.: "The extra Pharmacopoeia", 1996, ROYAL PHARMACEUTICAL SOCIETY, LONDON, XP002068051, 224540 *
STANTON ET AL.: "A MONOCLONAL ANTIBODY WHICH MIMICKS GLYCINE ACTIONS ON N-METHYL-D-ASPARTATE RECEPTORS HAS COMPLEX EFFECTS ON CHANNEL ACTIVATION AND NEURONAL SENSITIVITY TO HYPOXIA", SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 16, no. 1, 1990, pages 88, XP002068024 *
WAHLESTEDT ET AL.: "Antisense oligodeoxynucleotides to NMDR-R1 receptor channel protect cortical neurons from excitotoxicity and reduce focal ischemic infartions", NATURE, vol. 363, no. 6426, 1993, pages 260 - 263, XP002068025 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003505514A (ja) * 1999-07-28 2003-02-12 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルベニア 破骨細胞生成を阻害する方法
WO2002050302A2 (fr) * 2000-12-21 2002-06-27 Myriad Genetics, Inc. Interactions proteine-proteine
WO2002050302A3 (fr) * 2000-12-21 2003-01-23 Myriad Genetics Inc Interactions proteine-proteine
WO2006094674A1 (fr) * 2005-03-07 2006-09-14 Michael Hermanussen Antagonistes de recepteur nmda dans l'intervention medicale de troubles metaboliques

Also Published As

Publication number Publication date
CA2280722A1 (fr) 1998-08-20
EP0971712A1 (fr) 2000-01-19
GB9703109D0 (en) 1997-04-02
ZA981206B (en) 1999-03-26
AU6001798A (en) 1998-09-08
JP2001513757A (ja) 2001-09-04

Similar Documents

Publication Publication Date Title
AU2005274852B2 (en) FLT3 inhibitors for immune suppression
JP2549643B2 (ja) 神経変性症の予防及び治療における特異的ｎーメチルーｄーアスパラギン酸エステルレセプター拮抗剤としての用途
JP2006176542A (ja) フェニルエテンスルホンアミド誘導体含有医薬
NZ536603A (en) A combination of an NMDA-antagonist and acetylcholine esterase inhibitors for the treatment of Alzheimer's disease
HUT77920A (hu) Opiát antagonistát és kalciumsókat tartalmazó gyógyászati készítmények és alkalmazásuk
KR20050094843A (ko) 욕지기, 구토, 구역질 또는 이들의 조합을 치료하는 방법
NZ529944A (en) Active ingredient combination of (e.g. galanthamine or desoxypeganine with acamprosate or memantine) for treating narcotic or alcohol addiction
WO2001008705A1 (fr) Remedes contre les douleurs neurogenes
KR101318806B1 (ko) 메틸페니데이트 유도체 및 그 용도
IL262816A (en) Combination of pure 5 – ht6 receptor antagonists with nmda receptor agonist
EP0971712A1 (fr) Compositions permettant d'inhiber la resorption osseuse
BG107810A (bg) Използване на селективни допамин-d4-рецепторни агонисти за лечение на сексуална дисфункция
AU684711B2 (en) Use of 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine for the treatment of pain and oedema
EP3197445A1 (fr) Proline ou dérivés de proline pour le traitement de la démence
KR101016927B1 (ko) 알츠하이머 질환의 치료용 ｎｍｄａ 길항제 및 아세틸콜린에스테라제 억제제의 조합물
JP3272369B2 (ja) イミダゾール誘導体を含有する抗ｈｉｖ組成物
WO2007081061A1 (fr) Agent therapeutique utilise contre les douleurs neurogenes
AU2015201106B2 (en) Methylphenidate derivatives and uses of them
CZ20022177A3 (cs) Sloučenina pro pouľití při léčení bolesti a farmaceutický prostředek obsahující tuto sloučeninu
EP0958820A1 (fr) Utilisation d'un dérivé imidazolé pour la fabrication d'un médicament déstiné au traitement de maladies autoimmunes
JPH1160483A (ja) Ｔｎｆ産生阻害剤
JP2001261560A (ja) トログリタゾンを含有する運動神経細胞の変性又は死の阻害剤
EP1003517A1 (fr) Composition pharmaceutique de traitement de ce qu'on appelle les jambes sans repos
JP2000191533A (ja) 鎮痛剤
Reddel Current management options in myasthenia gravis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 1998 535477

Country of ref document: JP

Kind code of ref document: A

Ref document number: 2280722

Country of ref document: CA

Kind code of ref document: A

Ref document number: 2280722

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1998903203

Country of ref document: EP

Ref document number: 60017/98

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 09367353

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1998903203

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1998903203

Country of ref document: EP